Volume 62, Issue 1, Pages (January 2015)

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.

Volume 61, Issue 2, Pages (August 2014)

Volume 63, Issue 1, Pages (July 2015)

Volume 46, Issue 3, Pages (March 2007)

Inflammasomes in liver diseases

Volume 61, Issue 4, Pages (October 2014)

Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

m-TOR inhibitors: What role in liver transplantation?

MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis Wichit Srikureja,

m-TOR inhibitors: What role in liver transplantation?

Volume 68, Issue 5, Pages (May 2018)

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

Volume 44, Issue 4, Pages (April 2006)

NS5A inhibitors in the treatment of hepatitis C

Immigration and viral hepatitis

Volume 66, Issue 1, Pages 1-4 (January 2017)

Ype P. de Jong, Charles M. Rice, Alexander Ploss Journal of Hepatology

Living donor liver transplantation: is the hype over?

Volume 59, Issue 4, Pages (October 2013)

Volume 42, Issue 4, Pages (April 2005)

Mesenchymal stromal cell therapy for liver diseases

Reply to: “DCD consensus and futility in liver transplantation”

Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection Anaïs Vallet-Pichard,

Jordan J. Feld, Graham R. Foster Journal of Hepatology

Hepatitis C core protein – The “core” of immune deception?

Volume 61, Issue 1, Pages S108-S119 (November 2014)

Burcin Ekser, Eric Lagasse Journal of Hepatology

Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel

Volume 44, Issue 1, Pages (January 2006)

A dive into the complexity of type I interferon antiviral functions

Volume 61, Issue 1, Pages S69-S78 (November 2014)

Volume 62, Issue 3, Pages (March 2015)

Management of cirrhosis due to chronic hepatitis C

Ribavirin ante portas: Uptake transporters into hepatocytes dissected

Darius Moradpour, Arash Grakoui, Michael P. Manns

Autophagy in the liver Journal of Hepatology

EASL Clinical Practice Guidelines: Wilson’s disease

Volume 58, Issue 4, Pages (April 2013)

Volume 64, Issue 2, Pages (February 2016)

Roberto de Franchis, Aleksander Krag Journal of Hepatology

Volume 44, Issue 2, Pages (February 2006)

Economics of chronic hepatitis B and hepatitis C

Volume 41, Issue 4, Pages (October 2004)

Volume 65, Issue 2, Pages (August 2016)

Hepatology may have problems with putative surrogate outcome measures

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Volume 67, Issue 5, Pages (November 2017)

Immigration and viral hepatitis

Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability Markus Cornberg,

HCV targeting of patients with cirrhosis

Immunological techniques in viral hepatitis

The impact of intestinal microflora on serum bilirubin levels

Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential rather than concomitant administration with pegylated interferon and ribavirin? Lawrence.

Volume 63, Issue 1, Pages (July 2015)

Volume 51, Issue 2, Pages (August 2009)

The use of hemospray in portal hypertensive bleeding; a case series

Volume 66, Issue 3, Pages (March 2017)

Volume 62, Issue 3, Pages (March 2015)

m-TOR inhibitors: What role in liver transplantation?

Liver transplantation in children

Pathogenesis of cholestatic hepatitis C

Chimeric mouse model of hepatitis B virus infection

Volume 50, Issue 1, Pages 4-6 (January 2009)

Volume 54, Issue 6, Pages (June 2011)

Genetics of hepatocellular carcinoma: The next generation

Reversion of disease manifestations after HCV eradication

Presentation transcript:

Volume 62, Issue 1, Pages 234-237 (January 2015) Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon- free, NS3/NS4A inhibitor-based treatment. A case report Roberto Rossotti, Giovanna Travi, Annamaria Pazzi, Chiara Baiguera, Enrica Morra, Massimo Puoti Journal of Hepatology Volume 62, Issue 1, Pages 234-237 (January 2015) DOI: 10.1016/j.jhep.2014.09.031 Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Viral load and leukocyte cell counts during antiviral treatment and 24weeks after the end of therapy. Dashed lines show total leukocyte and lymphocyte counts; absolute values are indicated on the left axis, lymphocyte percentage values are indicated at any time point. Wk, week; PT-Wk, post-treatment week. (This figure appears in colour on the web.) Journal of Hepatology 2015 62, 234-237DOI: (10.1016/j.jhep.2014.09.031) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions